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Abstract
Urinary cotinine is one of the most commonly measured biomarkers reflecting recent exposure to 
nicotine. In some cases a simple qualitative dichotomization of smokers and non-smokers is all 
that is required. NicAlert® test strips have been evaluated for this purpose, but other recently 
introduced, inexpensive single-line test strips have not. In this study we evaluated two such strips 
with nominal cutoffs of 200 and 10 ng/mL. A total of 800 urine samples with known cotinine 
concentrations determined by an LC–MS-MS method were examined, including 400 urine 
samples ranging from 0.23 to more than 24,000 ng/mL by the 200 ng/mL strip, and 400 samples 
with concentrations <200 ng/mL by the 10 ng/mL cutoff strip. Both test strips performed well in 
these evaluations. Classification relative to LC–MS-MS by the 200 ng/mL strips had a sensitivity 
of 99.5% and specificity of 92%, with 95.8% accuracy. The 10 ng/mL strips had a sensitivity of 
98.7% and specificity of 90.1%, with 93.3% accuracy. The positive predictive value for the 200 
ng/mL strips was 92.6% and the negative predictive value was 99.5%. For the 10 ng/mL strips, the 
corresponding values were 85.4 and 99.2%, respectively. The prevalence of positive samples was 
50% in the 200 ng/mL group, and 37% in the 10 ng/mL set. Each strip was read by two readers 
with an overall agreement of >98%. Our results suggest that these simple and inexpensive lateral 
flow immunoassay test strips can provide useful qualitative estimates of nicotine exposures for 
appropriate applications within the inherent limitations of sensitivity and precision of the 
immunoassay test strip format.
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Introduction
Tobacco use and cessation studies often include measurements of cotinine, a primary 
nicotine metabolite, as a biomarker of exposure. These assays are typically conducted in 
readily accessible matrices such as urine or saliva (1–3). Sensitive liquid-chromatography 
tandem mass spectrometry assays for accurately measuring cotinine in blood, urine, saliva 
and other matrices are well-established and available in several academic, government and 
commercial laboratories (3). The reliable performance of these assays in both serum and 
urine has been documented by inter-laboratory evaluations (4, 5). However, while these 
assays are valuable and indeed essential for many studies, they also are relatively time-
consuming and expensive, and laboratory capacity is often limited. Therefore, for certain 
less demanding purposes such as an initial separation of presumed tobacco users from non-
users, or confirming compliance in smoking cessation programs, investigators may consider 
the use of accessible and relatively inexpensive non-laboratory based tests such as exhaled 
carbon monoxide measurements or the use of lateral flow immunoassay (LFIA) cotinine test 
strips (3). The latter are of particular interest since unlike CO measurements which reflect 
recent exposure to combustion by-products (e.g. from smoking), cotinine assays are specific 
for nicotine exposure.
To date, most literature reports concerning the use of cotinine test strips in urine or saliva 
have used Nymox NicAlert®, which is a multilevel device consisting of several “reland” 
bands with varying affinities for cotinine which is described as providing semi-quantitative 
results. NicAlert® strips are based on a standard competitive LFIA approach for each band 
based on the use of monoclonal cotinine antibodies and colloidal gold nanoparticles for 
visual detection. The performance of NicAlert® strips in estimating urine or saliva cotinine 
concentrations has been evaluated and reported previously by several authors (6–10).
More recently, newer LFIA strips for urine or in some cases saliva cotinine measurements 
have become available based on a traditional design with a single test band with a defined 
cutoff value. For urine samples, the nominal strip cutoff level for smokers vs non-smokers is 
usually set by the manufacturer to 200 ng/mL (3), although lower cutoff levels are also 
available. These newer cotinine LFIA devices are significantly less expensive than 
NicAlert® strips and are widely available online as over-the-counter (OTC) devices from 
many suppliers. However, unlike NicAlert®, there is presently no information available on 
the reliability of these newer strips other than the limited insert reports that are (usually) 
provided by the manufacturers. In this study we evaluated the performance of two LFIA 
cassette devices purchased from on-line suppliers, and compared them relative to the total 
cotinine concentrations as measured by LC tandem mass spectrometry in a total of 800 urine 
samples.
Materials and Methods
Test devices
We purchased urinary cotinine test strips in cassette format (DCT-102–200) with a reported 
cutoff of 200 ng/mL (COT200) from CLIAwaived (https://www.cliawaived.com, 1578 
Sorrento Valley Road, San Diego, CA 92121), and another set of test strip cassettes 
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(DCT-102) with a 10 ng/mL cutoff concentration (COT10) from All Test (http://
www.custom-monoclonalantibody.com, 550 Yinhai Street, Hangzhou 310018, PR China). 
All strips were individually packaged in sealed pouches with desiccant, and were opened 
immediately prior to use. The CLIAwaived test strips were all lot number COT602004 and 
those from All Test were lot number COT17060012.
Urine samples
The urine samples used in this study were residual frozen aliquots from samples that had 
been analyzed as part of the NIH-FDA Population Assessment of Tobacco and Health 
(PATH) study (11, 12). Westat’s Institutional Review Board approved the study design and 
data collection protocol including cotinine measurements for PATH. All samples had been 
analyzed for total cotinine, trans-3′-hydroxycotinine and usually several other analytes by 
one of two fully validated LC tandem mass spectrometry methods depending on the 
concentration levels (7, 13, 14). The total dataset from which these samples were drawn 
consisted of 10,263 samples, ranging in total cotinine concentration from 0.23 to 24,900 
ng/mL. For the COT200 test strips we divided the dataset into two subsets with samples 
either above or below 200 ng/mL for total cotinine. The two sets were then sorted by 
increasing concentration and every nth sample from that set was selected for analysis. A 
total of 400 samples were selected overall with 200 from each of the two subsets. For the 
COT10 strips we selected 400 samples from the low subset (200 ng/mL or less of total 
cotinine), again by selecting every nth sample from the ranked set for a distributed range of 
values. Of the total 800 samples, 22 (2.8%) were included in both data sets.
Analysis
LFIA assays were conducted according to the manufacturer’s directions. Urine vials were 
completely thawed and well-mixed prior to assay. Packs were opened immediately before 
use and 80 μL of well-mixed urine was pipetted into the sample well. The strips were placed 
on the bench and left to develop for 5 min at which point the results (presence or absence of 
colored bands) were independently read and recorded by two analysts who were blind to the 
identity of the samples. LFIA strips were coded as negative (i.e. below the defined cutoff 
concentration) if any red color was visible in the test band region; otherwise they were coded 
as positive. All control bands were visible in each case, confirming normal development. 
Data were collected over time by entry into an Excel file, and the final results were 
processed using SAS, version 9.4 (SAS Institute, Cary, NC).
Results
Table I summarizes the results obtained for both test devices in this study. The agreement 
between the two independent readers was excellent at 98–99% in both cases. There was 
seldom any ambiguity in interpreting the bands. The results given in Table I are based on 
those of the primary reader (H.A.) only, since test strips would normally be evaluated by a 
single individual.
Figure 1A and C shows the log distribution of the selected samples for the COT200 and 
COT10 test strips, respectively. For a classification based on 200 ng/mL of total cotinine, the 
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a priori prevalence of positive samples in the COT200 group was 50%. For the COT10 
classification group the prevalence of positive samples was 37% (148/400). Figure 1B and D 
shows the range of individual classification results for the corresponding dataset (COT200 or 
COT10) as a function of concentration.
When constrained to samples with narrower limits around the nominal cutoff concentration, 
the strips retained good sensitivity although the specificities were noticeably lower. COT200 
strips used to classify a subset of 63 samples with total cotinine concentrations between 10 
and 500 ng/mL had a sensitivity of 92.8% and specificity of 67.3%. COT10 strips applied to 
147 urine samples with total cotinine concentrations within the range 1–20 ng/mL had a 
sensitivity and specificity of 93.9 and 72.8%, respectively.
ROC analyses of the COT200 and COT10 results (not shown) resulted in AUC values of 
0.9970 and 0.9914, respectively. The optimum cutoff concentration point estimated from a 
logistic model for COT200 was 126.2 ng/mL based on the maximum Youden’s J index. The 
corresponding value for the COT10 model was 5.3 ng/mL. In both cases the effective cutoff 
value of the strips was lower (~53–63%) than the stated cutoff concentration.
Reclassification of the COT200 test strip data based on a cotinine cutoff of 126.2 ng/mL 
improved the specificity with values for sensitivity and specificity of 97.6 and 95.7%, 
respectively. Similarly, reclassification of the COT10 results using a total cotinine value of 
5.3 ng/mL also improved the results with sensitivity and specificity of 95.3 and 95.7%, 
respectively. However, any increase in specificity necessarily reduces the sensitivity, and the 
optimum classification efficiency of nicotine exposures typically will encompass a 
concentration range rather than a single point estimate.
Discussion
Our results indicate that simple, inexpensive LFIA devices are capable of providing good 
results in the qualitative screening of urine samples for their cotinine content. It should be 
noted that our analysis was specifically of the prediction of total urinary cotinine cutoffs by 
the test strips relative to LC–MS-MS concentrations, and did not address reported tobacco 
use status of the individuals. The cotinine concentration of spot urine samples is generally 
regarded as a good estimate of recent nicotine intake, but it is known to be subject to 
substantial variability both within and between individuals (15), and urinary cotinine 
concentrations among similarly active tobacco users may differ. Hydration and relative 
concentration differences of samples is another established issue that may be partially 
addressed by creatinine adjustments, although the value of such corrections remains 
controversial (16, 17). Consequently, classification of an individual as a smoker or non-
smoker from a single urine analysis is not definitive even when sophisticated and reliable 
assays such as LC–MS-MS are used. However, in most cases the difference in urinary 
cotinine concentration between regular smokers and non-smokers is several orders of 
magnitude.
As can be seen in Figure 1B and D, all misclassified values using either strip were in the 
vicinity of the nominal cutoff concentration and were predominately false positives. For 
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COT200 strips the false positive concentrations ranged from 196 down to as low as 30 
ng/mL. The false negative result sample had a concentration of 260 ng/mL. With COT10 
strips the false positive samples had total cotinine concentrations of 1.8–9.6 ng/mL; the two 
false negatives were 11.2 and 11.8 ng/mL. Outside of those limits, all samples were 
correctly classified.
Trans-3′-hydroxycotinine is another important metabolite in urine that often is more 
abundant than cotinine. Furthermore, cotinine and hydroxycotinine may exist in both free 
and glucuronide forms. Our LC–MS-MS assays were of total cotinine following hydrolysis 
of the glucuronides, and included the sum of both forms in the sample. Conversely, our 
evaluation of the LFIA cassettes with pure standards indicated that they were not sensitive to 
cotinine-N-glucuronide and thus the test strips likely measured only the free cotinine form. 
However, some cross-reactivity with standards of both free hydroxycotinine and its O-
glucuronide was observed and this might have contributed to at least some misclassifications 
since with both strips, the misclassified groups had hydroxycotinine/cotinine ratios that 
averaged twice as high (4.4 vs 2.2) as the correctly classified samples.
Although our results indicate that good classification efficiency can be obtained with these 
LFIA cotinine test strips, there are a number of limitations. One of the major problems of 
LFIA continues to be reproducibility between strips which at least partly reflects the 
complexity of the preparation, handling and storage of these devices. In addition, the number 
of different companies providing OEM (Original Equipment Manufacturer) sourcing and the 
difficulty in determining the provenance of a local suppliers products is a concern. Of the 
two cassettes that we evaluated in this study, the COT10 devices were manufactured by All 
Test, but we could not confirm the source of the COT200 product, although it may also have 
been All Test. Until greater transparency is available concerning the manufacture and 
sourcing of these devices, care in selecting cotinine LFIA suppliers is important. 
Nevertheless, our results indicate that these relatively new, low cost LFIA test strips for 
cotinine are capable of providing useful initial qualitative screening information on the 
urinary cotinine concentrations of individuals when appropriately applied to the types of 
studies for which they are suited.
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Figure 1. 
Sample distributions and classification accuracies by concentration. Panels (A) and (C) are 
the log distributions of the samples selected for use with the COT200 and COT10 test strips, 
respectively. Panels (B) and (D) are the classification results relative to concentration for 
COT200 and COT10 samples, respectively. Results labeled “Correct” were properly 
classified based on the stated cutoffs for the test strips. The results labeled “Error” are 
incorrect classifications, including both false positive and false negative results. The vertical 
lines represent the nominal cutoff concentration for the test strip. The classifications found 
for the samples analyzed with the COT200 strips were: true positive = 199, false positive = 
16, true negative = 184, false negative = 1. For the COT10 strips the corresponding values 
were: true positive = 146, false positive = 25, true negative = 227, false negative = 2.
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